🔗 Permalink

Inventor profile of:

Pascale Andre

City:

Marseilles

Country:

France

Published Applications:

Last publication date:

2021-08-05

Top Assignees for applications by Pascale Andre

The entities that hold a legal rights for patent applications filed by inventor Andre Pascale:

INNATE PHARMA 10 Marseilles, France
Innate Pharma SA 4 Marseille, France
Innate Pharma 3 Marseille, France
BRISTOL-MYERS SQUIBB COMPANY 3 Princeton, NJ United States
Innate Pharma, S.A. 3 Marseilles, France
Innate Pharma S.A.S. 2 Marseilles, France
University of Genova 2 Genoa, Italy
UNIVERSITY OF GENOA 2 GENOA, Italy
Novo Nordisk A/S 2 Bagsvaerd, Denmark
Novo-Nordisk A/S—Novo Alle 1 Bagevaerd, Denmark
INNATE PHARMA S.A.S 1 Marseille, France
INNATE PHARMA SA 1 Mareille, France
BRISTOL-MYERS SQUIBB COMPANY 1 Princeston, NJ United States
Novo-Nordisk A/S - Novo Alle 1 Bagevaerd, Denmark
UNIVERSITA DI GENOVA 1 Genova, Italy

Recent patent applications by Andre Pascale

Pascale Andre from Marseilles, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2021-08-05

US20210238285A1

Chemistry; metallurgy

Treatment regimens using anti-NKG2A antibodies

#2 | 2020-10-22

US20200332008A1

Chemistry; metallurgy

Neutralization of inhibitory pathways in lymphocytes

#3 | 2019-10-24

US20190322744A1

Chemistry; metallurgy

Treatment of cancers using anti-NKG2A agents

#4 | 2019-01-31

US20190031755A1

Chemistry; metallurgy

Neutralization of inhibitory pathways in lymphocytes

#5 | 2018-05-03

US20180117147A1

Human necessities

Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

#6 | 2017-11-02

US20170313773A1

Chemistry; metallurgy

Treatment of cancers using anti-NKG2A agents

#7 | 2017-10-19

US20170298131A1

Chemistry; metallurgy

Treatment regimens using anti-NKG2A antibodies

#8 | 2017-10-12

US20170291947A1

Chemistry; metallurgy

Neutralization of inhibitory pathways in lymphocytes

#9 | 2016-09-08

US20160257750A1

Chemistry; metallurgy

Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma

#10 | 2015-10-08

US20150283234A1

Human necessities

Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

#11 | 2015-05-07

US20150125464A1

Chemistry; metallurgy

Monoclonal antibodies against NKG2A

#12 | 2013-09-26

US20130251711A1

Human necessities

Methods for treatment of recurrent hematological malignancies

#13 | 2012-12-27

US20120328615A1

Chemistry; metallurgy

Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders

#14 | 2012-08-16

US20120208237A1

Chemistry; metallurgy

Nucleic acids encoding human anti-kir antibodies

#15 | 2010-11-18

US20100291110A1

Chemistry; metallurgy

Compositions and methods for regulating NK cell activity

#16 | 2009-08-20

US20090208416A1

Human necessities

Monoclonal antibodies against NKG2A

#17 | 2009-03-26

US20090081240A1

Chemistry; metallurgy

Human anti-KIR antibodies

InventorID:

6014036 ⎘